+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Constipation Treatment Market- Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 111 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896164
The constipation treatment market will show rapid growth due to factors such as increasing geriatric population and changing dietary habits, high prevalence of IBS-C, OIC, and chronic constipation, and the development of the latest drugs and treatment procedures.

The irritable bowel syndrome (IBS) is found to be a chronic, recurring, and remitting functional disorder of the gastrointestinal tract that causes abdominal pain, distention, and changes in bowel habits. Irritable bowel syndrome (IBS) is found affecting up to 7%-18% of the population worldwide and therefore its prevalence is increasing that is driving the overall market. Although there are several drugs for IBS in the market that are effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed.

There are also newer pharmacological treatments being available for constipation that is superior to placebo in relieving constipation. But there is no single approach to treat IBS-C. Often, people use a mix of therapies to get relief. They can include changes in diet, exercise, stress management, and medication. Hence all these factors are associated with the increase in the overall growth of the market.

Key Market Trends

Laxatives are Expected to Dominate the Constipation Market During the Forecast Period

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu-opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. And the laxatives are a type of medicine that can treat constipation. They're often used if lifestyle changes, such as increasing the amount of fiber in your diet, drinking plenty of fluid, and taking regular exercise, have not helped.

Therefore over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment.

North America is Expected to Dominate the Constipation Market During the Forecast Period

North America is found to be the largest growing region of the market, and it is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. Furthermore, the U.S. holds the largest market share in the North America region owing to factors such as the presence of a large number of market players manufacturing medications for constipation.

Asia Pacific is also expected to be the fastest-growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of GI diseases.

Competitive Landscape

The heavy investments are being made by manufacturers towards the development of novel therapeutic drugs for constipation and are expected to fortify the global market. These ardent efforts by the manufacturers of therapeutic drugs for the treatment of constipation have aided the growth of the global market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population and Changing Dietary Habits
4.2.2 High Prevalence of IBS-C, OIC and Chronic Constipation
4.2.3 Development of Latest Drugs and Treatment Procedures
4.3 Market Restraints
4.3.1 Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapeutic
5.1.1 Laxatives
5.1.2 Chloride Channel Activators
5.1.3 Peripherally Acting Mu-Opioid Receptor Antagonists
5.1.4 GC-C Agonists
5.1.5 Others
5.2 By Disease Type
5.2.1 Chronic idiopathic constipation (CIC)
5.2.2 Irritable bowel syndrome with constipation (IBS-C)
5.2.3 Opioid-induced constipation (OIC)
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Takeda Pharmaceutical Company Ltd.
6.1.2 Ironwood Pharmaceuticals, Inc.
6.1.3 Salix Pharmaceuticals, Inc.
6.1.4 Abbott Laboratories
6.1.5 AstraZeneca Plc
6.1.6 Cosmo Pharmaceuticals NV
6.1.7 Sanofi S.A.
6.1.8 Bayer AG

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takeda Pharmaceutical Company Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Salix Pharmaceuticals, Inc.
  • Abbott Laboratories
  • AstraZeneca Plc
  • Cosmo Pharmaceuticals NV
  • Sanofi S.A.
  • Bayer AG